microdosing glp 1 for mcas GLP-1s in with Dr. Tania Dempsey - Mast Cell Matters: Deep dives on MCAS with Tania Dempsey, MD - Presented by The POTScast GLP-1 Medications and Microdosing: What

LLYs forward P/E contracted from 35.55x in March 2025 to 25.90x today, per TIKR data, reflecting the markets recalibration of GLP-1 growth expectations rather than any deterioration in the business itself

The findings consistently demonstrate that, irrespective of whether the follow-up period was 1, 3, or 5 years, SGLT2i users exhibited a lower risk of developing PsA compared to GLP-1 RA users

Heres a closer look

Daily use may be helpful when gut barrier integrity, microbial diversity, or metabolic signaling is compromised

Limited human data suggest no increased risk of major birth defects with early accidental exposure